Obeticholic Acid for Prevention in Barrett's Esophagus
NCT04939051 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is recruiting participants. It studies Obeticholic acid and Placebo Administration in Barrett Esophagus and Esophageal Adenocarcinoma. The registry lists an enrollment of 30 participants at 8 sites in 1 country. The registry lists a start date of 3 Jan 2024 and a primary completion date of 1 Sept 2027. 2 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04939051 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | National Cancer Institute (NCI) |
| Enrollment | 30 |
| Registered sites | 8 |
| Countries | 1 |
| Conditions | Barrett Esophagus and Esophageal Adenocarcinoma |
| Drugs | Obeticholic acid and Placebo Administration |
| Start | 3 Jan 2024 |
| Primary completion | 1 Sept 2027 |
| Study completion | 1 Sept 2027 |
| Last update posted | 18 Nov 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Prashanthi Thota
University of Michigan Rogel Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Kansas Cancer Center
Kansas City
Ajay BansalRecruiting
- Recruiting
- Washington University School of Medicine
St Louis
Dayna S. EarlyRecruiting
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill
Nicholas J. ShaheenRecruiting
- Recruiting
- Cleveland Clinic Foundation
Cleveland
Prashanthi ThotaRecruiting - Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland
Joseph E. WillisNot, yet, recruiting - Not, yet, recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04939051
Each answer restates registry values shown on this page.
What is NCT04939051?
NCT04939051 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Obeticholic acid and Placebo Administration in Barrett Esophagus and Esophageal Adenocarcinoma.
Is NCT04939051 recruiting?
As of 21 Nov 2026, it is recruiting participants. 6 of its 8 sites list their own status as recruiting.
Who leads NCT04939051?
The registry names Prashanthi Thota (principal investigator, University of Michigan Rogel Cancer Center) as the overall official.
Where does NCT04939051 run?
The registry lists 8 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04939051 study?
The registered drug and biological interventions are Obeticholic acid and Placebo Administration.
When is NCT04939051 expected to complete?
The registry lists a primary completion date of 1 Sept 2027 and a study completion date of 1 Sept 2027. The sponsor last updated the record on 18 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.